💊Takeda Divests Techpool to Joint-Venture Partners in China
Osaka, Japan, May 21, 2018 — Takeda Pharmaceutical Company Limited (TSE: 4502) (“Takeda”) today announced it has entered into an agreement to sell its majority shareholding of 51.34% in Guangdong Techpool Bio-Pharma Co (Techpool), a leader in the research, discovery and marketing of urinary protein biopharmaceuticals and production of biopharmaceuticals in critical care.
The shareholding is to be acquired in an all-cash, combined Stock Purchase Agreement by Takeda’s joint venture partner in Techpool: Shanghai Pharmaceutical Holding Co. Ltd. (Shanghai Pharma SSE ticker: 601607, HKEx ticker: 2607) and a fund managed by SFund International Investment Fund Management Limited, a wholly-owned subsidiary of Guangzhou Industrial Investment Fund Management Co., Ltd (“the Fund”).
The agreement remains subject to approval from the State Administration for Market Regulation in the People’s Republic of China.
The Base Payment for the purchase price of Takeda’s shareholding is US$280 million.